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Abstract
Current rhinometric and flow assessments measure nasal patency and are often
poorly correlated with rhinitis symptoms. To evaluatemagnetic resonance imaging
(MRI) as a new method to measure inflammatory changes in nasal and sinus
mucosa following nasal allergen challenge. A pilot study (n¼ 6) determined
the optimal technical settings for MRI to measure inflammatory change which
were then adopted for the main study. This study was a single blind, placebo-
controlled, three-way crossover trial in 14 subjects with seasonal allergic rhinitis.
Effects of cetirizine, cetirizine and pseudoephedrine (CetþPE), or placebo on total
nasal symptom scores (TNSS), peak nasal inspiratory flow (PNIF), nasal nitric
oxide (nNO), acoustic rhinometry, and MRI end points following nasal intranasal
allergen challenge were measured. There were significant changes in all parameters
after allergen challenge (P< 0.01), except for nNO. MRI end points were less
variable and more consistent than PNIF and acoustic rhinometry in detecting
changes after allergen challenge. Total nasal airspace volume was the most sensitive
and reproducibleMRImeasurement, with amean reduction from5.37 cm3 (95%
CI7.35,3.38; P< 0.001), which was maximal 60min after allergen challenge. A
change of one in TNSS corresponded to a change in MRI volume of 0.57 cm3.
There was an improvement in all parameters (except nNO) in subjects taking
CetþPE compared with placebo, however this did not achieve significance
probably because of the small study size (overall analysis P> 0.07; comparison of
active versus placebo P> 0.09). MRI provides novel insights into the anatomical
inflammatory changes post allergen challenge and provides a new method for
assessment of nasal patency and objective measurement of inflammatory
responses.
Introduction
Nasal provocation has been used to investigate the
pathophysiology of allergic and non-allergic rhinitis, and
is thought to have potential value for the evaluation of
mechanisms of inflammation in both upper and lower
airways, because of the similarity of the inflammatory
responses to allergen challenge [1]. Traditionally, the
evaluation of therapies for allergic rhinitis have used
symptom-based scores (total nasal symptom score; TNSS)
or visual analog scale (VAS) methods, despite the subjective
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nature and high variability of these tests [2–5]. There is a
need for more objective and reproducible biomarkers of
allergic inflammation which are non-invasive to facilitate the
clinical assessment of novel anti-inflammatory drugs.
H1-receptor antagonists (anti-histamines) are widely
prescribed for the treatment of allergic rhinitis but
have limited clinical efficacy. Anti-histamines may relieve
symptoms of itch, sneeze, and discharge but are less effective
treatments for nasal blockage. Nasal blockage may result
from oedema and vascular congestion. Therefore, the
combination of the antihistamine cetirizine (Cet) [6] and
a decongestant, such as pseudoephedrine (PE), has a logical
rationale [7, 8].We compared the effect of single doses of Cet
(10mg) alone or Cet (10mg) and PE (120mg) in
combination versus placebo to evaluate MRI end points
against symptom scores (TNSS, VAS, and nasal symptom
score for congestion NSSC), measurements of nasal
patency [4, 9], acoustic rhinometry, peak nasal inspiratory
flow (PNIF), acoustic rhinometry of nasal volume and
minimum cross sectional area (ARMXCA) and nasal nitric
oxide (nNO) [10–12]. The study was conducted in two parts,
with an initial pilot phase to determine the relevant MRI
parameters and a second study as a single-blind three-way
cross over study.
Methods
Subjects
Asymptomatic subjects with a diagnosis of seasonal allergic
rhinitis and a previous positive skin prick test for Timothy
grass pollen at or within the 12 months preceding the
screening visit were selected. Six subjects were recruited to
part 1 of the study. Fourteen subjects were randomized in
part 2, this included the six subjects from part 1. All
subjects were included in the analysis, the average age
of subjects was 31 years with a male to female ratio of
12:2. Full details of the subject characteristics at baseline
can be found in the supplemental data online (Table SI).
This prospective study was approved by the East London
and the City Research Ethics Committee (07/Q0603/3)
and written informed consent was obtained from all
subjects.
Pilot study to optimize MRI parameters
A pilot study (data not shown) determined the technical
parameters for MRI imaging and the optimal times to
perform MRI scans post allergen challenge. Two MRI
scans were performed after the allergen challenge: an
early scan after 15–30min and a second scan at 45–60min.
The MRI data were reviewed by a radiologist and
MRI parameters were defined for all subsequent scans
in the main study (see Results). The optimal time to
perform the MRI scan was found to be at 60min post-
challenge when there were maximal inflammatory changes.
However, at this time point the TNSS response was
submaximal at 80% of the peak response which occurred at
the earlier 15min time point as we have previously
described [13].
Controlled trial of rhinitis therapies
The study design is shown in Figure 1. This was a
randomized, single-blind, placebo-controlled, double-dum-
my, three period, crossover single oral dose study in patients
with allergic rhinitis. Subjects were assessed at baseline with
MRI scan, symptom scores, plus measurements of nasal
patency. The same order of investigations were repeated at
the different time points throughout the study. Subjects were
then dosed according to the randomization code. Subjects
were blindfolded before each dose administration. Active
treatments and double dummy placebo were administered
with 50mL water and tablets swallowed under direct
observation by the study nurse. The study medications
were as follows: CONTACT 120mg (pseudoephedrine
hydrochloride). Zirtek 10mg (cetirizine hydrochloride).
There were matching placebo tablets for both Zirtek, and
CONTACT 120.
TheMRI scan and all measurements were repeated 60min
after drug administration and immediately before the
allergen challenge procedure. Nasal allergen challenge was
then performed (see below). The final MRI scan was
repeated at 60min post-allergen challenge and all other
measurements repeated. Each treatment period was separat-
ed by a wash-out period of at least 7 days. This time period
allowed the nasal mucosal process to return to a non-
symptomatic baseline.
Nasal allergen challenge
Nasal allergen challenge was performed as previously
described [1, 13] with Timothy grass pollen (Alk-Abello,
Figure 1. Study design with MRI assessments at baseline, 60min after
drug (pre-challenge) and 60min after allergen challenge. PNIF, peak
nasal inspiratory ﬂow; VAS, visual analog scale.
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Denmark). Application of the allergen to the nasal mucosa
was undertaken using a nasal pump spray (Dolphin nasal
applicator, Valois [14–16]. A total dose of 1mg was given as
100mL to each nostril (500 BU/mL to each nostril).
Acoustic rhinometry and PNIF
Rhinometry was performed at screening pre-challenge pre-
dose, and 60min after challenge. Rhinometry assessments
were made of nasal volume and minimum cross sectional
area (ARMXCA) using an A1 acoustic rhinomter (GM
Instruments, Kilwinning, UK). With a nosepiece inserted,
subjects were asked to breathe in and hold their breath. The
measurement was repeated three times. PNIF andmaximum
PNIF (PNIFMAX) were measured with a Portable Nasal
Inspiratory Flow Meter (Clement Clark, Harlow, UK), with
full exhalation beforehand. The PNIF was a short, sharp
inspiratory action of approximately one second duration
within an anesthetic mask tightly applied to the face. The
measurement was repeated three times and the highest result
recorded.
nNO
nNO was measured using the NIOX analyser (Aerocrine,
Stockholm, Sweden) with sample time of 40 s, with tidal
breathing for approximately 5 s. The subject inhaled to total
lung capacity over 2–3 s with the mouth open, then closed
the mouth and held the breath as long as possible. Sample
flow did not fall more than 1.5mL/s below its normal value
(around 5mL/s). The procedure was repeated to obtain
three readings within 10% of each other.
Symptoms
Patient assessment of nasal patency was performed using
VAS 0–100mm. and TNSS completed by the subject. TNSS
were recorded before and at frequent intervals after nasal
allergen challenge. Nasal congestion, rhinorrhoea, sneezing,
and nasal itch were scored from 0 to 3 (0 no, 1 mild, 2
moderate, 3 severe symptoms). The scores were then added
up to give a final TNSS out of a maximum of 12.
MRI measurements
MRI measurements were made using a Siemens 1.5T MRI
scanner (Siemens Heathcare, Erlangen, Germany) with an
average scan time for each subject approximately 15min.
Settings were 4–5min for proton density (PD) and
transverse relaxation time (T2) coronal views (4–5min)
with 40 slices, the dimensions were field of view (the size of
the two dimensional spatial encoding area of the image;
160 143mm2), matrix (384 205) and voxel size
(0.7 0.4 0.3mm3); time to equal (PD weighting¼ 43ms;
T2 weighting¼ 128ms); time to repeat (6120ms). Cross-
sectional airspace area (and thus also airspace volume) of the
nasal passages was measured. Within subject, the cross-
sectional airspace area is directly proportional to the airspace
volume per slice.
The primary endpoint was average airspace sectional
area (METASV). Secondary MRI endpoints were: volume
of fluid identified adjacent to the airspace; total mucosal
surface area (TMSA); total nasal cavity volume (TNCV; a
single value which could be applied to all time points per
patient—either the single value derived following image
registration, or the average of the values used for each time
point per patient visit) and nasal tissue volume (NTV)
derived from the nasal cavity volume less airspace and fluid
volumes (the resulting volume included cartilage, bone,
enclosed airspace and other factors and was only indicative
of the tissue volume).
All MRI endpoints were considered in two ways:
regularly defined intervals along the nasal passage, to
allow standardized subject profiles to be plotted, and totals
or averages along the entire length of the nasal passage to
provide a simple subject-level summary at each time point
(additionally, the smallest cross-sectional airspace area in
any slice along the nasal passage and the location of this
slice was determined). The maximum number of slices per
subject was 21 so location specific MRI measurements were
derived over 20 slices. MRI assessments of congestion
included: total airspace volume (TASV), METASV,
minimum cross-sectional area (MIXA), TNCV, and
TMSA.
Statistics
This exploratory study was not formally powered, but was
based on feasibility and exploratory statistics were used.
Subjects were randomized with RANDALL. All statistical
analyses were performed using SAS1 on a windows or UNIX
platform. Most displays were generated in the harmoniza-
tion of Analysis and Reporting Program environment which
uses SAS version 8.2 on a UNIX platform. Trellis plots were
generated using S-Plus version 7.0. Average air space
sectional area was analyzed by mixed effect model, looking
at change from baseline at pre- and post-challenge. The
model used fitted terms for baseline value, period, treatment,
time and treatment–time interaction. The average baseline
TNCV was explored as a covariate. The UNR correlation
structure between time points was used. Subject was fitted as
random variable. Point estimates and 95% confidence
intervals were constructed using the appropriate variance
term for the estimating the change from baseline at pre- and
post-challenge and the difference between pre- and post-
challenge for each treatment. The Kenward Roger correction
B. R. Leaker et al. MRI changes following nasal allergen challenge
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was employed. Estimates of both within- and between-
subject variability were calculated for future studies, with
95% confidence intervals based on Satterthwaite’s approxi-
mation. Similar models were used to analyse MIXA, TASV,
and TMSA as well as normalized airspace volume (TNCVm).
Similar models, but without adjusting for TNCV at baseline,
were used to analyse total NTV (TNTV) and normalized
nasal tissue. Acoustic rhinometry endpoints: nasal volume
and MIXA, VAS, and PNIF changes from baseline were also
analysed in a similar way to MRI endpoint without the
adjustment for TNCV.
Results
Pharmacodynamic marker results
Allergen challenge produced a significant change across all
measurements (Fig. 2 and Table 1). The individual data for
TNSS pre- and post-allergen challenge for the different
treatment periods are shown in Figure 3. The mean change
and changes from baseline for TNSS was D6.55 (95%CI 4.16,
8.94;P< 0.001), PNIFwasD28.77 (95%CI46.58,10.96;
P< 0.002), and VAS was D26.67 (95%CI 12.20, 4114;
P< 0.001). For the MRI measurements, the change from
Figure 2. Panels for measurements pre-dose and post-nasal allergen challenge for the different treatment groups. (A) Nitric oxide (NO), (B) total nasal
symptom score (TNSS), (C) peak nasal inspiratory ﬂow (PNIF), (D) nasal volume, (E) total airspace volume (TASV), (F) normalized TASV, (G) normalized total
nasal tissue volume (TNTV). Data are mean SD.
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baseline values were; TASV D5.37 (95%CI 7.35, 3.38;
P< 0.001), NTVD5.47 (95%CI 3.25, 7.70; P< 0.001), TMSA
D37.74 (95%CI61.40,14.08;P< 0.003). TMSAalsowas
also reduced by allergen, mean difference D37.74 (95%CI
61.40, 14.08; P< 0.03).
The variability in the intra-subject response and the
different methodologies employed were NSSC 1.08 (95%CI
0.85, 1.53); PNIF 38.32 (95%CI 29.68, 54.11); TASV 2.98
(95%CI 2.30, 4.21); TNSS 3.63 (95%CI 2.82, 5.09); VAS
22.07 (95%CI 16.98, 31.53). The lowest intra-subject
variability was seen with MRI measurement of TASV. The
MRI profile with slice is shown in Figure 4 and typical MRI
images pre- and post-allergen challenge shown in Figure 5.
The changes in volume in a typical subject are clearly seen
and a unilateral predominance in some subjects (Fig. 5B).
There is some indication of correlation between the MRI
and acoustic rhinometry volume (ARV), and some degree of
negative correlation between MRI and VAS score. A change
of one in the TNSS score on average corresponded with MRI
volume of 0.57 cm3, with a range of 0.78 to 0.37. The
correlation data can be viewed in the supplemental data
online (Figures S1 and S2).
There was a trend towards difference between treatment
and placebo although this did not achieve significance
because of small numbers (Fig. 2; P¼ 0.32); across allergen
challenge the differences between time-points were highly
significant (P< 0.001). There was no evidence of an
interaction between time and treatment (P> 0.1).
Overall across all treatments (Fig. 2 and Table 2) the
airspace sectional area tended to decrease after challenge.
The drop was less pronounced for the combination
treatment Cet plus PE, although not significantly different
from placebo. Similar results were obtained when analysing
airspace volume. The graphical analysis shows the trend for a
treatment separation that did not reach statistical signifi-
cance but illustrates the lower variability withMRI than with
other methods (Table 2).
VAS, TNSS, and PNIF
There was no evidence of treatment difference or treatment
time interaction (all P> 0.5) and, overall across all treat-
ments, the VAS increased after challenge (P< 0.001; Fig. 2).
The increase was less pronounced for the combination
treatment Cet plus PE, although not significantly different
from placebo. The TNSS results were similar to those of VAS
(Fig. 2). PNIF showed a trend to fall after allergen challenge
and across all treatment groups (Fig. 2).
Acoustic rhinometry
There was no evidence of difference between treatments or
an interaction between time and treatment (P> 0.1; Table 2).
There was evidence of difference between time points
(P< 0.001; Fig. 2 and Table 1). The trend was similar to the
one observed when analysing the MRI METASV.
nNO
There were no significant changes in nNO across the allergen
challenge procedure (Fig. 2). On placebo pre-dose values
Table 1. Changes induced by allergen challenge in the presence of
treatment can be detected by most endpoints (LS means (95%CI) of
treatment estimate of change from pre-challenge).
Treatment Estimate Lower Upper P
NSSC
Cet 1.72 0.96 2.48 0.001
Cet þ PE 1.31 0.53 2.08 0.002
Placebo 1.41 0.64 2.18 0.001
PNIF
Cet 36.29 59.14 13.45 0.003
Cet þ PE 13.31 35.27 8.65 0.227
Placebo 33.48 55.43 11.54 0.004
TASV
Cet 4.29 6.32 2.27 0.001
Cet þ PE 2.28 4.23 0.32 0.024
Placebo 3.76 5.80 1.73 0.001
TNSS
Cet 6.40 3.97 8.84 0.001
Cet þ PE 4.77 2.32 7.21 0.001
Placebo 6.83 4.38 9.29 0.001
VAS
Cet 27.08 13.64 40.52 0.001
Cet þ PE 20.17 6.73 33.61 0.004
Placebo 26.76 12.79 40.72 0.001
Cet, cetirizine; PE, pseudoephedrine; NSSC, nasal symptom score for
congestion; PNIF, peak nasal inspiratory ﬂow; TASV, total airspace
volume; TNSS, total nasal symptom score; VAS, visual analog score.
Figure 3. Total nasal symptom score (TNSS) pre-allergen challenge (after
dosing) and 60min post-nasal allergen challenge for individual subjects
with the different treatments.
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were 1304 762 ppb; post-dose 1699 485; post-challenge
1509 522; Cet treated group pre-dose valuewas 1587 565;
post-dose 1609 500; 1599 523 post-challenge. In the
combination group, the values were pre-dose 1574 589;
post-dose 1904 500; post-challenge 1570 430. The data
showed no significant change (Fig. 2) following allergen
challenge.
Safety
There were no serious adverse events reported. The MRI
scans and procedure was well tolerated. Adverse events were
mostly related to the allergen challenge and were mild in
nature and self-limiting.
Discussion
This is the first study in man to evaluate nasal allergen
responses using MRI imaging before and after nasal allergen
challenge. Animal studies have reported the effect of nasal
challenge in response to histamine and methacholine on
MRI images using gadolinium enhancement to localize
edema formation [17–21]. Clinically, MRI has mainly been
used for the evaluation of the para-nasal sinuses and may
replace CT for the evaluation of pathological mucosal
abnormalities [22, 23]. A recent report describes the use of
MRI to evaluate the inflammation produced by segmental
bronchial allergen challenge [24].
Nasal allergen challenge produced a highly significant
change in all the measured variables including all MRI
endpoints. The timing and magnitude of the changes seen
after allergen challenge seen in this study for symptom-based
scores and measurements of nasal patency were similar to
that reported in a recent review, which included a dose-
response analysis to nasal administration of nasal aller-
gen [1]. Therefore, the findings in our study that MRI
endpoints, particularly TASV, were more sensitive and less
variable than the conventional measurements of symptom
scores and nasal patency would suggest that MRI may prove
a useful and objective method for assessment of
the inflammatory response post-allergen challenge. A
negative change is indicative of smaller free nasal airspace.
A drop in airspace volume was expected after allergen
challenge. A smaller negative change from baseline would
represent a lower reaction from the nasal tissues to the
allergen challenge and that would then be reflected in wider
free nasal airspace.
The clearest separation of the different treatments was
seen in the MRI measures of the volume of the respiratory
space and the soft tissue, normalized total nasal tissue
volume (TNTV; Fig. 2). An advantage ofMRI is the ability to
measure mucosal inflammatory changes and edema as well
as volume changes directly.
In some instances, the changes in volume were localized to
one side, as shown in Figure 5B. This is consistent with an
asymmetry of nasal volume changes post-allergen challenge,
(with greater changes on the non-patent side) which was
related to the endogenous nasal cycling rhythm [25].
Measures of cross- sectional area have been compared
between MRI and acoustic rhinometry [26], although the
extent of the correlation has been reported to depend on
the state of congestion which limits its value in challenge
Figure 4. Box plot of MRI versus standardized slice number with total airspace volume (TASV)mm for placebo group (10 yellow, blue 60, and red
120min relative to dosing with allergen). Bars represent median, upper and lower quartiles, whiskers represent 5–95% percentiles. Outliers are
represented as symbols o and x.
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studies [27]. The lack of correlation between the different
variables illustrates the difficulty in utilization of symptom-
based scores to assess the effects of nasal challenge [3, 4, 28]
and it should be pointed out that one method for assessment
is not adequate for allergic rhinitis assessment and that
multiple methods should be used. There was a weak
correlation between the MRI and ARV, and a weak negative
correlation between MRI and VAS (supplemental data).
A lack of correlation with symptom VAS score and
cross-sectional area measurements by acoustic rhinometry
was also seen in a histamine challenge [29]. No difference
was seen in nNO data. The baseline values are in the range
reported by Kharitonov [30] and somewhat higher than
the values in normal controls reported in other studies [31].
However, the effects of nasal allergen challenge are varied
with decreases in nNO reported [30], or no change [32],
probably dependent on the degree of sinus obstruction.
The lack of a clear difference between drug treatments and
placebo may have been due to the single dose administration
of active drugs and restricted time-point analysis. The study
was not powered to show statistically significant differences
between drug treatments and placebo. There was a clear
trend that suggested a positive treatment effect after
combination therapy (CetþPE); the data showed a reduc-
tion in symptom scores, improvement in nasal patency, and
MRI end points (Fig. 2), although statistical significance was
not achieved perhaps because of the small numbers involved
(n¼ 14). These changes may result from the effect of PE in
reducing vascular congestion and edema. Other studies have
also demonstrated that the combination of anti-histamines
with vasoconstrictor agents increases efficacy in the
treatment of allergic rhinitis [7, 12].
By contrast, a single dose of Cet failed to abrogate the
effects of allergen challenge and post-allergen measurements
were no different from placebo. A similar lack of effect of Cet
on nasal patency as recorded by acoustic rhinometry
(MIXA) has also been reported [29]. Antihistamines have
minimal effects on nasal congestion, which remains one of
the less well-treated symptoms of allergic rhinitis. After
single dosing with anti-histamines, effects are typically seen
on cutaneous topical challenge wheal and flare responses up
to 24 h after a single dose [33]. More often effects of anti-
histamines have been examined after chronic dosing. The
Figure 5. (A) MRI at baseline and at 60min following challenge; subject
1 shows decreased airspace in both nostrils, the changes are
representative for all but one of the subjects where the baseline scan
showed movement artifact; (B) MRI at baseline and at 60min following
challenge; subject 2 shows unilateral changes with decreased airspace in
right nostril, increased airspace in left nostril.
Table 2. Effect of allergen challenge on MRI endpoints. LS means
(95%CI) of treatment comparison for change from pre-challenge.
Treatment Ref Test-ref Lower Upper P
NSSC
Cet Cet þ PE 0.41 0.46 1.27 0.34
Cet þ PE Placebo 0.31 0.56 1.17 0.47
Placebo Placebo 0.10 1.00 0.79 0.82
PNIF
Cet Cet þ PE 22.98 53.80 7.84 0.14
Cet þ PE Placebo 2.81 33.50 27.88 0.85
Placebo Placebo 20.17 9.98 50.33 0.18
TASV
Cet Cet þ PE 2.02 4.43 0.39 0.10
Cet þ PE Placebo 0.53 2.99 1.92 0.66
Placebo Placebo 1.49 0.92 3.90 0.21
Cet, cetirizine; PE, pseudoephedrine; NSSC, nasal symptom score for
congestion; PNIF, peak nasal inspiratory ﬂow; TASV, total airspace
volume; TNSS, total nasal symptom score; VAS, visual analog score.
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effect of anti- histamines is greatest on the itching and
sneezing symptoms scores [28], typically measured at steady
state. However, in a study comparing skin and nasal
responses of five anti- histamines, inhibitory effects were
seen after single dosing [11]. Additionally, single dose
studies with anti-histamines using the Vienna Chamber [34]
showed significant reductions in symptoms score of
approximately 30% within 1 h post-dosing, but with much
larger sample sizes (n¼ 65). Evidence of synergy of the
effects has been previously reported for the combination of
PE and Cet in chronic dosing studies [7, 8]. Differences
between single dose and multiple dose effects are also seen in
other studies with theophylline [35] and with cortico-
steroids, where acute and chronic effects seen with inhaled
corticosteroids differ when administered immediately before
challenge corticosteroids have a small effect on early phase
symptoms and inhibit predominantly the late phase TH2
mediated responses (IL-4, -5, -13) [15, 16]. In contrast,
multiple dosing with corticosteroids inhibits symptoms in
the early phase (approximately 30% [15, 36] and attenuates
predominantly the late phase production of TH2 cytokines
in response to allergen challenge [15, 36]. Changes in the
airway calibre measured with acoustic rhinometry with
corticosteroids, showed a trend but did not reach statistitical
significance again in contrast to effects of inhaled cortico-
steroid on symptom scores [37]. The variability of
rhinometric measurements varies from 10% to 30% and is
beset by intrinsic problems of the non-linear relationship
between flow and volume [4]. Additionally, expressing the
rhinometric measurements as a minimal cross sectional area
to depict resistance is complicated by non-uniform flow and
change between laminar and turbulent flow [9, 38].
This is the first reported study of the use ofMRI where this
technique has been used to quantify the inflammatory
changes following nasal allergen challenge. MRI endpoints
have been compared directly with conventional assessments,
such as symptom scores and measurements of nasal patency,
although subjective measures might be variable, they are a
good indication to how the participant perceives their
allergic rhinitis symptoms, and currently the FDA recognizes
TNSS as the only parameter in evaluating new medications,
while still considering others. The major MRI limitations
remain cost, imaging time, and the potential for claustro-
phobia. MRI procedures were well tolerated in this small
study despite the need to keep perfectly still following
allergen challenge, and the acquisition times prevent
multiple frequent measurements. MRI provides an objective
method for the assessment of the response to nasal challenge,
which merits further study in studies with chronic dosing
and novel agents. MRI provides novel insights into the
anatomical changes in response to allergen and provides a
new method for the assessment of nasal patency, vascular
congestion, and inflammation.
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SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s web-site.
Figure S1. Correlation data from MRI for total airspace
volume (TASV) versus total nasal symptom score (TNSS).
The changes between pre-challenge and post-challenge are
plotted. Parameter estimates; 95% confidence limits; slope
0.57 (0.78, 0.37).
Figure S2. Trellis plot of MRI derived measurement
versus acoustic rhinometry data, all time points all data.
The average airspace volume is directly proportional to
the total airspace volume. The black box outlines the MRI
analyses; total airspace volume (TASV), average airspace
sectional area (METASV), minimum cross-sectional area
(MIXA), total mucosal surface area (TMSA) and total
nasal cavity volume (TNCV). Data for the visual analog
scale score (VASCR), acoustic rhinometry distance of
minimal cross-sectional area (ARDX), acoustic rhinom-
etry volume (ARV), acoustic rhinometry cross-sectional
area (ARX), Maximum peak nasal inspiratory flow
(PNIFMAX). There are indications of correlation bet-
ween the MRI assessments and more conventional
endpoints and suggestions of greater correlations between
VASCR and ARV (cells with red box outline). Symbols:
þ placebo, o cetirizine, D cetirizineþ pseudoephedrine;
red 60min post-challenge, green post-dose, blue pre-
challenge.
Table S1. Demographic characteristics of seasonal rhinitis
subjects studied. Data are mean  SD.
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